太平洋时间2025年8月13日,2025年世界肺癌大会(World Conference on Lung Cancer, WCLC)官网公布了本届大会入选的研究摘要信息,其中包括复宏汉霖PD-L1 ADC HLX43首次人体I期临床研究的更新数据。该研究的完整更新数据将于西班牙当地时间2025年9月8日下午2:31-2:39,在WCLC大会壁报导览环节由牵头主要研究者中国医学科学院肿瘤医院王洁教授报告,敬请关注。
HLX43是一款靶向程序性死亡-配体1(PD-L1)的广谱抗肿瘤ADC,兼具免疫检查点阻断与载荷细胞毒性的双重作用机制。临床前研究显示,HLX43在PD-1/PD-L1单抗耐药的非小细胞肺癌、宫颈癌、食管鳞癌等多个瘤种中显示出显著疗效,且耐受性良好。在2025 美国临床肿瘤学会(ASCO)年会上,HLX43的I期临床数据首次发布,展现出令人鼓舞的初步疗效和安全性,对鳞状/非鳞状非小细胞肺癌(NSCLC),有无EGFR突变、有无脑/肝转移、PD-L1阳性/阴性的NSCLC患者都展现了优异的治疗潜力,且安全性良好。
根据此次更新的摘要信息,HLX43在晚期实体瘤、尤其是绝大多数接受过检查点抑制剂(CPI)治疗并失败的后线耐药NSCLC患者中,持续表现出高应答率,在特定亚组如EGFR野生型非鳞状NSCLC人群中,HLX43展现了更为优异的疗效,客观缓解率(ORR)达47.4%,同时延续了良好的安全性。值得关注的是,HLX43在PD-L1阳性/阴性/未知患者人群中皆显示良好的疗效,不依赖肿瘤标志物筛选:
有望改写后线耐药NSCLC患者困局:截至2025年2月28日,共计85名患者接受了HLX43治疗,其中21名晚期实体瘤患者和64名NSCLC患者分别被纳入Ia期(剂量递增阶段)和Ib期(剂量扩展阶段)研究,88.2%(75/85)的患者在入组前曾接受过检查点抑制剂(CPI)治疗并失败。
NSCLC疗效优异,特定亚群更显著:在76名NSCLC患者(69名患者可评估疗效)中,ORR为31.9%(22/69),疾病控制率(DCR)为87.0%(60/69)。亚组分析结果显示,HLX43在特定人群中疗效更好:Ib期2 mg/kg和2.5 mg/kg组分别达到了38.1%(8/21)和33.3%(7/21)的ORR;CPI耐药的NSCLC患者(n=61)ORR达32.8%(20/61),EGFR野生型非鳞状NSCLC患者(n=19)ORR达47.4%(9/19)。
安全性良好,延续高效低毒潜力:在Ia期,4 mg/kg组观察到1例剂量限制性毒性事件,涉及发热性中性粒细胞减少症。95.2%的患者报告了治疗相关不良事件(TRAE),主要为1-2级。发生3级及以上TRAE的患者为5例(23.8%),均来自3 mg/kg和4 mg/kg组,最常见的为中性粒细胞计数降低(19%)、白细胞计数降低(19%)和贫血(14.3%)。值得关注的是,本研究中报告了免疫相关不良事件(irAE),提示HLX43可通过免疫激活机制强化抗肿瘤疗效;同时报告irAE患者人群ORR得到提升。
不依赖生物标志物筛选:在PD-L1阳性NSCLC患者(n=50)ORR为32.0%(16/50),而PD-L1阴性/未知的患者(n=19)ORR为31.6%(6/19),未显示明显差异。
HLX43在标准治疗失败的晚期NSCLC患者中,包括在PD-(L)1抑制剂治疗后进展的患者中展现出优异的抗肿瘤活性和可控的安全性,高效低毒的特质提示其具备进一步拓展至一线疗法的潜力。目前,HLX43 Ib期扩展队列研究仍在入组中。期待HLX43的疗效和安全性在多项研究中持续验证,为以非小细胞肺癌为代表的晚期难治实体瘤患者带来更好的治疗方案。
关于复宏汉霖
复宏汉霖(2696.HK)是一家国际化的创新生物制药公司,致力于为全球患者提供可负担的高品质生物药,产品覆盖肿瘤、自身免疫疾病、眼科疾病等领域,已有6款产品在中国获批上市,4款产品在国际获批上市,6个上市申请分别获中国药监局、美国FDA和欧盟EMA受理。自2010年成立以来,复宏汉霖已建成一体化生物制药平台,高效及创新的自主核心能力贯穿研发、生产及商业运营全产业链。公司已建立完善高效的全球创新中心,按照国际药品生产质量管理规范(GMP)标准进行生产和质量管控,不断夯实一体化综合生产平台,其中,公司商业化生产基地已相继获得中国、欧盟和美国GMP认证。
复宏汉霖前瞻性布局了一个多元化、高质量的产品管线,涵盖约50个分子,并全面推进基于自有抗PD-1单抗H药汉斯状®的肿瘤免疫联合疗法。截至目前,公司已获批上市产品包括国内首个生物类似药汉利康®(利妥昔单抗)、自主研发的中美欧三地获批单抗生物类似药汉曲优®(曲妥珠单抗,美国商品名:HERCESSI™,欧洲商品名:Zercepac®)、汉达远®(阿达木单抗)、汉贝泰®(贝伐珠单抗)、全球首个获批一线治疗小细胞肺癌的抗PD-1单抗汉斯状®(斯鲁利单抗,欧洲商品名:Hetronifly®)以及汉奈佳®(奈拉替尼)。公司亦同步就19个产品在全球范围内开展30多项临床试验,对外授权全面覆盖欧美主流生物药市场和众多新兴市场。
Release of the Updated Abstract for Henlius’ PD-L1 ADC HLX43 at 2025 WCLC
On August 13, 2025, Pacific Time, the official website of the 2025 World Conference on Lung Cancer (WCLC) released the selected research abstracts for this year’s conference, Among the highlights is the updated abstract for the first-in-human Phase 1 clinical trial of HLX43, Henlius’ PD-L1 ADC. The full set of updated data will be presented in poster tour session at the WCLC by Professor Jie Wang from Cancer Hospital Chinese Academyof Medical Sciences, the Leading Principal investigator (PI) of this study, on September 8, 2025, from 2:31 to 2:39 PM in Spain.
HLX43 is a broad-spectrum anti-tumor ADC candidate targeting PD-L1, which exhibits dual mechanisms integrating immune checkpoint blockade and payload-mediated cytotoxicity. Preclinical data have shown that, HLX43 has good anti-tumour effects and a favorable tolerability profile in non-small cell lung cancer (NSCLC), cervical cancer (CC), esophageal squamous cell carcinoma (ESCC), and other tumour types that were PD-1/L1 mAb-resistant. The results from the phase 1 clinical trial of HLX43 has been first released at the 2025 ASCO Annual Meeting, demonstrating manageable safety profile and encouraging efficacy in various solid tumors especially in patients with NSCLC, including squamous and non-squamous NSCLC patients (sqNSCLC and nsqNSCLC), patients with or without EGFR mutation, patients with or without brain/liver metastasis, and PD-L1 positive or negative patients.
According to the updated abstract, HLX43 continues to demonstrate a high response rate in patients with advanced solid tumors, particularly in pretreated NSCLC patients who failed checkpoint inhibitor therapy. HLX43 exhibits superior efficacy in specific subgroups, with an objective response rate (ORR) of 47.4% in EGFR wild-type non-squamous NSCLC, while maintaining a favorable safety profile. Notably, HLX43 demonstrates robust efficacy regardless of PD-L1 expression, indicating its biomarker-independent antitumor potential.
Effective in Later-Line Treatment of CPI-Resistant NSCLC:As of February 28, 2025, a total of 85 patients received HLX43. In Phase Ia (dose-escalation), 21 patients with advanced solid tumors were enrolled, while in Phase Ib (dose-expansion), 64 NSCLC patients were recruited across three cohorts (2, 2.5, and 3 mg/kg). Notably, 88.2% (75/85) of patients failed prior checkpoint inhibitor (CPI) therapy.
Promising Efficacy in NSCLC with Notable Results in Specific Subgroups: Among the 76 NSCLC patients (69 efficacy-evaluable), ORR was 31.9% (22/69), with a disease control rate (DCR) of 87.0% (60/69). Subgroup analyses demonstrated promising efficacy of HLX43 in specific populations: the 2 mg/kg and 2.5 mg/kg cohorts in Phase Ib achieved ORRs of 38.1% (8/21) and 33.3% (7/21), respectively; CPI-refractory NSCLC patients (n=61) showed an ORR of 32.8% (20/61); EGFR wild-type non-squamous NSCLC patients (n=19) had an ORR of 47.4% (9/19).
Favorable Safety Profile, High Efficacy with Low Toxicity: In Phase Ia, one DLT event involving febrile neutropenia was observed in the 4 mg/kg group. Treatment-related adverse events (TRAEs) were reported in 95.2% of patients, mostly Grade 1-2. Grade ≥3 TRAEs occurred in 5 patients (23.8%), all from the 3 and 4 mg/kg cohorts, most frequently decreased neutrophil count (19%), decreased white blood cell count (19.0%) and anemia (14.3%). Immune-related adverse events (irAEs) reported in this study suggests HLX43 is capable of eliciting immunotherapeutic effects. Notably, patients who reported irAEs demonstrated a higher objective response rate (ORR).
Effective in different biomarker status: PD-L1-positive NSCLC patients (n=50) exhibited an ORR of 32.0% (16/50) while PD-L1-negative/unknown patients (n=19) achieved an ORR of 31.6% (6/19), with no significant difference observed.
In conclusion, HLX43 has demonstrated promising antitumor activity along with a manageable safety profile in patients with advanced NSCLC who were refractory to standard therapies, including those who had progressed after treatment with PD-(L)1 inhibitors. Its high efficacy with low toxicity traits support its potential in the first-line settings. Enrollment in the Phase Ib expansion cohort is ongoing. We anticipate the ongoing validation of HLX43's efficacy and safety across multiple studies, which could provide a superior treatment option for patients with advanced, refractory solid tumors, including those with non-small cell lung cancer.
About Henlius
Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 6 products have been launched in China, 4 have been approved for marketing in overseas markets, and 6 marketing applications have been accepted for review in China, the U.S. and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP.
Henlius has pro-actively built a diversified and high-quality product pipeline covering about 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as the backbone. To date, the company's launched products include HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANDAYUAN (adalimumab), HANBEITAI (bevacizumab), HANSIZHUANG (serplulimab, trade name: Hetronifly® in Europe), the world’s first anti-PD-1 mAb for the first-line treatment of SCLC, and HANNAIJIA (neratinib). What’s more, Henlius has conducted over 30 clinical studies for 19 products, expanding its presence in major markets as well as emerging markets.
联系方式
媒体:PR@Henlius.com
投资者:IR@Henlius.com
喜欢本文内容
点击下方按钮·分享 ·收藏 ·点赞 ·在看